Cashin, MD, chief medical officer, Novotech, shares insights on how sponsors and CROs can cultivate a “one team” mindset by setting the right leadership tone, encouraging collaboration, and leveraging ...

Brian Ongioni, chief product officer, uMotif, explains how early site feedback and patient involvement in software ...

Cashin, MD, chief medical officer, Novotech, shares why clear communication, strong leadership, and cultural alignment are essential to building effective partnerships between CROs, sponsors, and ...

Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation ...

New Phase III data published in The New England Journal of Medicine show elinzanetant, a nonhormonal dual NK-1/NK-3 receptor antagonist, significantly reduced vasomotor symptoms, improved sleep, and ...

Peter Ronco, CEO, Emmes, explains how the company is investing in transparent goal setting, comprehensive education, and ...

Cashin, MD, chief operating officer, Novotech, explains why seamless collaboration between CROs and sponsors is critical to advancing clinical trials, and reflects on Novotech’s recognition as ...

Findings from the primary analysis of the marginal zone lymphoma (MZL) cohort of the Phase II TRANSCEND FL (NCT04245839) trial showed significant and durable efficacy for Breyanzi(lisocabtagene ...